2007
DOI: 10.1002/cncr.23263
|View full text |Cite
|
Sign up to set email alerts
|

Kaposi sarcoma

Abstract: Despite major advancements, the optimal treatment for Kaposi sarcoma has yet to be defined. Comparable standards employing existing therapies to satisfactorily manage all epidemiologic forms of Kaposi sarcoma, and the utilization of mechanism‐based therapeutic strategies with innovative surrogate endpoints to appraise their efficacy, are required.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
1
0

Year Published

2010
2010
2013
2013

Publication Types

Select...
3
3

Relationship

1
5

Authors

Journals

citations
Cited by 6 publications
(1 citation statement)
references
References 17 publications
0
1
0
Order By: Relevance
“…3 In recent years there have been several changes in our understanding of KS, including its evolving epidemiology, pathogenesis, new clinical presentations and associations, descriptions of new histologic variants, and the emergence of novel biomarkers with promising targeted therapeutic agents. 4,5 Despite these advances, KS remains the most prevalent malignancy among patients with AIDS. Moreover, KS continues to plague patients with drug-related or transplant-associated immunosuppression.…”
mentioning
confidence: 99%
“…3 In recent years there have been several changes in our understanding of KS, including its evolving epidemiology, pathogenesis, new clinical presentations and associations, descriptions of new histologic variants, and the emergence of novel biomarkers with promising targeted therapeutic agents. 4,5 Despite these advances, KS remains the most prevalent malignancy among patients with AIDS. Moreover, KS continues to plague patients with drug-related or transplant-associated immunosuppression.…”
mentioning
confidence: 99%